1. Home
  2. EDSA vs APLT Comparison

EDSA vs APLT Comparison

Compare EDSA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edesa Biotech Inc.

EDSA

Edesa Biotech Inc.

HOLD

Current Price

$1.13

Market Cap

12.3M

Sector

Health Care

ML Signal

HOLD

Logo Applied Therapeutics Inc.

APLT

Applied Therapeutics Inc.

HOLD

Current Price

$0.10

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDSA
APLT
Founded
2015
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
14.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
EDSA
APLT
Price
$1.13
$0.10
Analyst Decision
Strong Buy
Hold
Analyst Count
2
2
Target Price
$13.00
$1.25
AVG Volume (30 Days)
95.7K
10.6M
Earning Date
02-10-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
N/A
$124.18
Revenue Next Year
N/A
$25.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.09
52 Week High
$4.49
$1.50

Technical Indicators

Market Signals
Indicator
EDSA
APLT
Relative Strength Index (RSI) 30.21 35.60
Support Level $0.94 $0.09
Resistance Level $1.34 $0.11
Average True Range (ATR) 0.12 0.01
MACD -0.03 0.01
Stochastic Oscillator 31.63 64.65

Price Performance

Historical Comparison
EDSA
APLT

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Share on Social Networks: